One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...

The Department of Veterans Affairs said it has stopped using the drug Avastin to treat eye disease, as it investigates concerns about serious infections and blindness from the drug, according to a ...

LOS ANGELES (Reuters) - Genentech Inc said on Thursday it will ban on November 30 direct purchases of Avastin by independent compounding pharmacies, which repackage the cancer drug as a low-cost ...

WASHINGTON, Dec 20 (Reuters) - Genentech Inc has resolved a dispute with doctors over the use of its cancer drug Avastin, a much less costly alternative to the biotech company's Lucentis for macular ...

The widely used cancer drug Avastin could save the eyesight of tens of thousands of people with age-related macular degeneration of the wet form, British researchers said Friday. The drug provides an ...

Here's some of the reaction from Wednesday's Food and Drug Administration advisory panel recommendation to remove approval of Avastin, developed by South San Francisco's Genentech, for use by women ...

WASHINGTON - The maker of the widely prescribed cancer drug Avastin is warning doctors and patients about counterfeit vials that have been distributed in the U.S. Roche's Genentech unit said Tuesday ...